Effectiveness of BNT162b2 XBB Vaccine against XBB and JN.1 Sub-lineages-Reference-Cited by-同舟云学术

Effectiveness of BNT162b2 XBB Vaccine against XBB and JN.1 Sub-lineages

Published:2024-05-06 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Tartof Sara Y.^ORCID,Slezak Jeff M.,Puzniak Laura,Frankland Timothy B.,Ackerson Bradley K.,Jodar Luis,McLaughlin John M.

Abstract

AbstractIn this Brief Report we provide updated results (October 11, 2023 through February 29, 2024) from our previously conducted test-negative case-control study in Kaiser Permanente Southern California to evaluate sub-lineage-specific effectiveness of the BNT162b2 XBB1.5-adapted vaccine. Results suggest that XBB1.5-adapted vaccines may have reduced effectiveness against JN.1 versus XBB sub-lineages.

Publisher

Cold Spring Harbor Laboratory

Reference11 articles.

1. U.S. Centers for Disease Control and Prevention. COVID Data Tracker: Monitoring Variant Proportions. Accessed December 18, 2023, https://covid.cdc.gov/covid-data-tracker/#variant-proportions

2. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1

3. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure

4. Effectiveness of the 2023–2024 Formulation of the COVID-19 Messenger RNA Vaccine

5. Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR Network Study;2024-07-07

2. Effectiveness of BNT162b2 XBB Vaccine against XBB and JN.1 Sub-lineages;2024-05-06